Literature DB >> 24949215

Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo.

Thambi Dorai1, Janane Diouri2, Orla O'Shea2, Stephen B Doty2.   

Abstract

A number of studies have focused on the beneficial properties of Curcumin (diferuloyl methane, used in South Asian cuisine and traditional medicine) such as the chemoprevention of cancer. Recent studies have also indicated that this material has significant benefits for the treatment of cancer and is currently undergoing several clinical trials. We have been interested in the application of this compound as a therapeutic agent for advanced prostate cancer, particularly the skeletal complications in this malignancy. Our earlier work indicated that this compound could inhibit the osteomimetic properties which occur in castration resistant prostate cancer cells, by interfering with the common denominators between these cancer cells and the bone cells in the metastatic tumor microenvironment, namely the osteoblasts and the osteoclast. We predicted that curcumin could break the vicious cycle of reciprocal stimulation that results in uncontrolled osteolysis in the bony matrix. In this work, we have evaluated the potential of this compound in inhibiting the bone metastasis of hormone refractory prostate cancer cells in an established animal model. Our results strongly suggest that curcumin modulates the TGF-β signaling that occurs due to bone matrix degradation by up-regulating the metastasis inhibitory bone morphogenic protein-7 (BMP- 7). This enhancement of BMP-7 in the context of TGF-βin the tumor microenvironment is shown to enhance the mesenchymal-to-epithelial transition. Most importantly, we show that as a result of BMP-7 up-regulation, a novel brown/beige adipogenic differentiation program is also up-regu- lated which plays a role in the inhibition of bone metastasis. Our results suggest that curcumin may subvert the TGF-βsignaling to an alternative adipogenic differentiation program in addition to the previously established interference with the osteomimetic properties, thus inhibiting the bone metastatic processes in a chemopreventive as well as therapeutic setting.

Entities:  

Keywords:  Bone Metastasis; Bone Morphogenic Protein-7; Curcumin; Osteomimetic Properties; Prostate Cancer; TGF-β; Tumor Microenvironment

Year:  2014        PMID: 24949215      PMCID: PMC4060744          DOI: 10.4236/jct.2014.54044

Source DB:  PubMed          Journal:  J Cancer Ther        ISSN: 2151-1934


  70 in total

1.  Cancer Incidence in Five Continents. Comparability and quality of data.

Authors:  D M Parkin; C S Muir
Journal:  IARC Sci Publ       Date:  1992

2.  Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage.

Authors:  Eva Kiss; Zoran V Popovic; Jens Bedke; Judith Adams; Mahnaz Bonrouhi; Andrea Babelova; Claudia Schmidt; Frank Edenhofer; Inka Zschiedrich; Sophie Domhan; Amir Abdollahi; Liliana Schäfer; Norbert Gretz; Stefan Porubsky; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

Review 3.  Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals.

Authors:  Bharat B Aggarwal
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

Review 4.  The biology of hormone refractory prostate cancer. Why does it develop?

Authors:  J T Isaacs
Journal:  Urol Clin North Am       Date:  1999-05       Impact factor: 2.241

5.  LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Authors:  G N Thalmann; R A Sikes; T T Wu; A Degeorges; S M Chang; M Ozen; S Pathak; L W Chung
Journal:  Prostate       Date:  2000-07-01       Impact factor: 4.104

Review 6.  Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis?

Authors:  Jeroen T Buijs; Maj Petersen; Geertje van der Horst; Gabri van der Pluijm
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

7.  Dietary intervention after definitive therapy for localized prostate cancer: results from a pilot study.

Authors:  J Kellogg Parsons; Vicky A Newman; James L Mohler; John P Pierce; Shirley Flatt; Karen Messer; James Marshall
Journal:  Can J Urol       Date:  2009-06       Impact factor: 1.344

Review 8.  Multitargeting by turmeric, the golden spice: From kitchen to clinic.

Authors:  Subash C Gupta; Bokyung Sung; Ji Hye Kim; Sahdeo Prasad; Shiyou Li; Bharat B Aggarwal
Journal:  Mol Nutr Food Res       Date:  2012-08-13       Impact factor: 5.914

9.  BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.

Authors:  Jeroen T Buijs; Cyrill A Rentsch; Geertje van der Horst; Petra G M van Overveld; Antoinette Wetterwald; Ruth Schwaninger; Niek V Henriquez; Peter Ten Dijke; Fran Borovecki; Regula Markwalder; George N Thalmann; Socrates E Papapoulos; Rob C M Pelger; Slobodan Vukicevic; Marco G Cecchini; Clemens W G M Löwik; Gabri van der Pluijm
Journal:  Am J Pathol       Date:  2007-09       Impact factor: 4.307

Review 10.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

View more
  17 in total

1.  Curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation.

Authors:  Hui Guo; Yuemin Xu; Qiang Fu
Journal:  Tumour Biol       Date:  2015-06-02

2.  Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells.

Authors:  Hui-Jun Hu; Xiao-Long Lin; Mi-Hua Liu; Xiao-Juan Fan; Wei-Wen Zou
Journal:  Oncol Lett       Date:  2015-12-28       Impact factor: 2.967

Review 3.  Therapeutic actions of curcumin in bone disorders.

Authors:  Ramin Rohanizadeh; Yi Deng; Elise Verron
Journal:  Bonekey Rep       Date:  2016-03-02

Review 4.  Naturally occurring compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog and WNT/β-catenin signalling pathways.

Authors:  L Farahmand; B Darvishi; K Majidzadeh-A; A Madjid Ansari
Journal:  Cell Prolif       Date:  2016-09-27       Impact factor: 6.831

5.  Curcumin-encapsulating Nanogels as an Effective Anticancer Formulation for Intracellular Uptake.

Authors:  Anna Reeves; Serguei V Vinogradov; Phil Morrissey; Mitchell Chernin; Mansoor M Ahmed
Journal:  Mol Cell Pharmacol       Date:  2015

Review 6.  Unraveling the Anticancer Effect of Curcumin and Resveratrol.

Authors:  Aline Renata Pavan; Gabriel Dalio Bernardes da Silva; Daniela Hartmann Jornada; Diego Eidy Chiba; Guilherme Felipe Dos Santos Fernandes; Chung Man Chin; Jean Leandro Dos Santos
Journal:  Nutrients       Date:  2016-11-10       Impact factor: 5.717

Review 7.  Cancer chemoprevention and therapy using chinese herbal medicine.

Authors:  Lijing Jiao; Ling Bi; Yan Lu; Qin Wang; Yabin Gong; Jun Shi; Ling Xu
Journal:  Biol Proced Online       Date:  2018-01-08       Impact factor: 3.244

Review 8.  The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.

Authors:  Inamul Haque; Arvind Subramanian; Chao H Huang; Andrew K Godwin; Peter J Van Veldhuizen; Snigdha Banerjee; Sushanta K Banerjee
Journal:  Int J Mol Sci       Date:  2017-12-31       Impact factor: 5.923

9.  Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling.

Authors:  Yuefeng Du; Qingzhi Long; Lin Zhang; Ying Shi; Xioagang Liu; Xudong Li; Bin Guan; Yanchao Tian; Xinyang Wang; Lei Li; Dalin He
Journal:  Int J Oncol       Date:  2015-10-13       Impact factor: 5.650

Review 10.  Structure-Based Classification and Anti-Cancer Effects of Plant Metabolites.

Authors:  Seong-Ah Shin; Sun Young Moon; Woe-Yeon Kim; Seung-Mann Paek; Hyun Ho Park; Chang Sup Lee
Journal:  Int J Mol Sci       Date:  2018-09-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.